Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-011: Sacituzumab Tirumotecan +/- Pembrolizumab vs Chemotherapy in 1L Advanced TNBC
NCT06841354Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- May 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival and Overall Survival. Started Mar 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06841354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841354.